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Abstract
Objective: The	aim	of	the	current	study	is	to	measure	long-term	executive	function,	
motor	outcome,	and	QoL	in	children,	adolescents,	and	young	adults	after	VAD	and	
Htx.
Methods: Patients	were	examined	during	routine	follow-up.	Investigation	tools	were	
used	as	follows:	Examination	for	MND	of	motor	outcomes,	Epitrack® for attention 
and	executive	functioning,	and	Kidscreen-52	and	EQ-5D-5L	questionnaires	for	QoL.	
Additional data were retrospectively obtained by an analysis of patient medical 
records.
Results: Out	of	145	heart	transplant	recipients	at	the	department	of	pediatric	car-
diology	of	the	University	Hospital	Munich,	39	were	implanted	with	a	VAD	between	
1992	and	2016.	Seventeen	(43.6%)	patients	died	before	or	after	Htx;	22	(56.4%)	pa-
tients	were	included	in	our	study.	Mean	age	at	transplant	was	9.52	years	(range:	0.58-
24.39	years,	median	9),	and	the	mean	follow-up	time	after	Htx	was	6.18	years	(range:	
0.05-14.60	years,	median	5.82).	MND	examination	could	be	performed	in	13	patients	
(normal	MND:	n	=	11,	simple	MND:	n	=	1,	complex	MND:	n	=	1).	Executive	function-
ing	was	tested	in	15	patients.	Two	(13.3%)	patients	had	good	results,	six	(40%)	aver-
age	 results,	 three	 (20%)	borderline	 results,	and	 four	 (26.7%)	 impaired	 results.	QoL	
(Kidscreen	n	=	7,	EQ-5D-5L	n	=	8)	was	similar	to	a	healthy	German	population.
Conclusion: Motor	 outcome,	 executive	 functioning	 and	 QoL	 in	 survivors	 of	 VAD	
bridging	therapy	and	Htx	can	be	good,	though	underlying	diseases	and	therapies	are	
associated	with	a	high	risk	of	cerebral	ischemic	or	hemorrhagic	complications.
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1  | INTRODUC TION
The	first	human	heart	transplant	was	performed	at	the	Groote	Schuur	
Hospital	in	Cape	Town	on	December	3,	1967.1	Since	then,	this	therapy	
has	gained	importance	for	the	treatment	of	end-stage	heart	failure,	
both in adult and in pediatric patients.2,3	 Increasing	 survival	 rates,	
associated	with	 tailored	 immunosuppression,	 are	 considered	 to	 be	
responsible for this trend.4,5	Nowadays,	HTx	is	an	established	treat-
ment option for terminal heart failure in children.6,7	 In	2014,	about	
11	000	pediatric	Htxs	worldwide	were	registered	by	the	ISHLT.7
However,	 long	 waiting	 times	 for	 a	 suitable	 pediatric	 donor	
organ underline the importance of optimizing therapy for patients 
on	the	wait	list.	Thus,	mechanical	circulatory	support	is	of	increas-
ing use.4,7
VAD	 are	 able	 to	 bridge	 time	 until	 transplantation	 (BTT),	
or	 in	 some	 cases,	 until	 recovery	 (BTR).	 According	 to	 the	 ISHLT,	
nearly	 30%	 of	 pediatric	 patients	 treated	 for	 terminal	 heart	 fail-
ure	between	2009	and	2015	needed	an	assist	device	as	bridge	to	
transplantation.5
Despite	satisfactory	initial	results	of	this	therapy,	long-term	con-
sequences should be assessed.8,9	Assist	device	implantations,	as	well	
as	 cardiac	 transplantations	and	prolonged	waiting	 times,	 can	have	
a severe impact on the psychological and physiological develop-
ment,	leading	to	a	limited	integration	of	young	adults	into	their	ed-
ucational,	professional,	and	social	environments.9-13	Risk	factors	for	
neurological and cognitive impairment around this therapy concept 
can	 be	 classified	 as	 preoperative	 (such	 as	 cerebral	 hypoperfusion	
due	 to	 congestive	 heart	 failure),	 intra-operative	 (eg,	 due	 to	 extra-
corporeal	 circulation	 and	 analgesic	 drugs),	 and	 postoperative	 (eg,	
cerebral	hypoperfusion	and	immunosuppressive	drugs).14-18	Further,	
VAD	therapy	poses	additional	risks	due	to	the	device	implantation,	
required	anticoagulation,	and	increased	risk	for	thrombosis,	but	also	
potential benefits for the preservation of intellectual function.13,19-21
Therefore,	the	aim	of	this	study	is	to	investigate	motor	outcomes	
and	executive	functioning,	as	well	as	the	HRQoL	in	children,	adoles-
cents,	and	young	adults	after	VAD	and	Htx.
2  | PATIENTS AND METHODS
All	pediatric	patients	who	received	an	assist	device	(BTT	or	BTR)	at	
the	LMU	Munich,	University	Hospital	between	1992	and	2016	were	
included and their medical records were reviewed.
To	assess	the	motor	and	executive	functioning	outcomes,	as	well	
as	the	HRQoL,	a	protocol,	including	the	specific	tests	outlined	below,	
was developed.
This study was approved by the local institutional ethics com-
mittee	and	was	executed	according	 to	 the	Declaration	of	Helsinki	
(1997)	 and	 subsequent	 revisions.	 Informed	 consent	 was	 obtained	
from	all	 individual	participants	 included	 in	 the	study.	Our	patients	
were	examined	in	the	setting	of	our	outpatient	clinic	during	a	routine	
follow-up.	Intraobservational	and	interobservational	variability	was	
assessed by comparing results. Reliability was reported and is sup-
ported by previous studies.22-28
2.1 | Assessment of MND
To	assess	motor	function	we	utilized	testing	for	MND.	It	is	based	on	
the	Touwen	 Infant	Neurological	 Examination,	 originally	 developed	
to monitor development in children.29 This standardized neurode-
velopmental	examination	is	mainly	part	of	clinical	practice,	but	it	is	
also	used	in	study	protocols,	particularly	in	neonatology,	to	investi-
gate and follow up on the development of preterm infants and new-
borns	at	risk.30
The	examination	 for	MND	 includes	 standard	 items	such	as	 re-
flexes,	 cranial	 nerve	 health	 motor	 and	 sensory	 functioning,	 body	
tone,	 and	 coordination.	 It	 contains	 eight	 domains	 of	 appreciation:	
posture	 and	muscle	 tone,	 reflexes,	 choreiform	 dyskinesia,	 coordi-
nation,	 fine	 manipulative	 ability,	 associated	 movements,	 sensory	
deficits,	 and	 cranial	 nerve	 function.	 It	 includes	 for	 these	 items	 an	
age-specific	 appreciation	 of	 the	 child's	 performance	 during	 exam-
ination with special attention given to involuntary and associated 
movements. Each domain is assessed by several different tests and 
can	be	appreciated	separately,	according	to	the	child's	performance.	
Subsequently,	a	distinction	can	be	made	between	a	normal	finding,	
and	a	simple	or	a	complex	MND,	based	on	the	number	of	dysfunc-
tional domains.
The accuracy and validity of this method were reported in previ-
ous	studies,	showing	a	good	to	excellent	test-retest	reliability.25,30,31
There	 are	 two	 different	 forms	 of	 MND:	 simple	 and	 complex	
MND.	 This	 classification	 is	 based	 on	 the	 number	 of	 dysfunctions	
present	(before	the	onset	of	puberty)	or	on	the	type	of	dysfunction	
(after	the	onset	of	puberty).	A	simple	MND	is	considered	to	be	in	the	
range of a “normal” neurological performance and is also described 
as	 “minor	 neurological	 difference”.	 In	 contrast,	 the	 presence	 of	 a	
complex	 MND	 reflects	 a	 neurological	 dysfunction	 and,	 regarding	
developmental	aspects,	is	strongly	related	to	learning	and	behavioral	
disorders.
We	used	 the	MND	examination	 forms	 to	 assess	patients	 aged	
6 years and older to detect even slight neurological deviations. All 
patients or the parents of underage children signed an informed 
K E Y W O R D S
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consent	form	for	video	documentation,	in	order	to	validate	the	re-
sults	by	a	pediatric	neurologist	(LG).
2.2 | Epitrack®
To	 assess	 the	 executive	 functioning	 of	 our	 patients,	 the	 Epitrack® 
test was used. This is a cognitive test instrument originally devel-
oped	as	a	15-minute	screening	 tool	 for	 the	detection	and	 tracking	
of cognitive side effects of both antiepileptic drugs and seizures in 
patients with epilepsy.32	The	EpiTrack®	test	comprises	six	subtests;	
these are borrowed from other well-established tests: The German 
“Kurztest	für	cerebrale	Insuffizienz”	(subtest	1);	the	Trail	Making	Test	
(subtests	2	 and	3);	 the	Chapuis	maze	 test	 (subtest	4);	 the	German	
“Leistungsprüfsystem”	 (subtest	5);	and	the	German	Wechsler	adult	
intelligence	scale—revised).26	The	6	subtests	are	(examined	function):	
(a)	interference	(response	inhibition),	(b)	connecting	numbers	(visual	
planning	and	psychomotor	speed),	(c)	connecting	numbers	and	circles	
(2	+	mental	flexibility	and	working	memory),	(d)	maze	test	(visuomo-
tor	anticipation),	(e)	word	fluency	(access	to	the	lexicon	using	a	pho-
nematic	algorithm),	and	 (f)	 inverted	digit	span	 (working	memory).33 
The	EpiTrack®	test	allows	for	the	quick	and	simple	screening	of	at-
tention	 and	 executive	 functioning,	 including	working	memory.26,32 
The	 reliability	of	 the	Epitrack® test has been reported in previous 
studies,	examining	277	 (Epitrack®	 junior)	and	689	 (Epitrack®	adult)	
patients	 in	total.	Some	of	these	patients	were	retested	after	a	few	
months,	achieving	a	retest	reliability	of	r	=	0.78	and	r	=	0.90.22,26,27 
This test has been described in previous studies as a valid and reliable 
screening	tool	for	the	assessment	of	executive	functioning.26
The	Epitrack® test is available in two different versions: a ju-
nior	(for	children	from	6	to	18	years	of	age)	and	an	adult	version.	
Total	scores	in	the	junior	version	range	from	6	to	56	points	and	are	
classified	 into	four	categories:	good	(≥36	points),	average	(31-35	
points),	borderline	(29-30	points),	and	impaired	(≤28	points).	The	
adult	version	 is	 scored	within	9-49	points,	 as	good	 (≥39	points),	
average	 (32-38	 points),	 borderline	 (29-31	 points),	 and	 impaired	
(≤28	points).
As	the	Epitrack®	 test	 is	 time-efficient,	shown	to	be	a	sensitive	
instrument	 for	 detecting	 problems	 with	 attention	 and	 executive	
functions,	and	has	also	been	used	in	research	fields	beside	epilepsy	
and	schizophrenia,	we	decided	to	include	the	Epitrack® test in our 
study.33-35
2.3 | Assessment of quality of life
The	QoL	of	 children,	 adolescents,	 and	 young	 adults	was	 assessed	
with	the	self-	and	proxy	version	of	the	Kidscreen-52	questionnaire	
(≤18	years).	It	was	completed	by	the	patient	(minimum	age:	8	years)	
and	their	parents	(for	patients	of	all	ages).	The	EQ-5D-5L	was	also	
used,	completed	by	the	patients	themselves	if	patients	were	adults	
at the time of follow-up.
2.3.1 | The Kidscreen-52 Questionnaire
The	Kidscreen-52	was	developed	by	the	Kidscreen	Group	Europe	
as	a	generic	and	cross-cultural	instrument,	which	is	available	in	32	
languages	(including	German).23,36,37	It	consists	of	10	dimensions:	
(a)	physical	well-being,	(b)	psychological	well-being,	(c)	moods	and	
emotions,	(d)	self-perception,	(e)	autonomy,	(f)	parent	relations	and	
home	 life,	 (g)	 financial	 resources,	 (h)	social	support	and	peers,	 (i)	
school	environment,	and	 (j)	 social	acceptance	and	bullying.	Each	
scale	consists	of	3-10	items	(52	items	in	total).	For	comparisons	of	
results,	there	is	a	representative	Kidscreen	population	of	22	827	
children	 and	 adolescents	 (8-18	 years)	 available.37 The reliability 
and	validity	of	the	Kidscreen	questionnaire	have	been	reported	in	
previous studies.23,37
2.3.2 | EQ-5D-5L
The	EQ-5D-5L	was	developed	by	the	EuroQoL	Group	as	a	standard-
ized,	generic	measure	of	health	status.38	It	consists	of	a	descriptive	
system	 and	 a	 VAS.	 The	 descriptive	 system	 comprises	 five	 dimen-
sions:	 (a)	mobility,	 (b)	self-care,	 (c)	usual	activities,	 (d)	pain/discom-
fort,	 and	 (e)	 anxiety/depression,	 each	 associated	 with	 5	 ordinal	
levels:	no/slight/moderate/severe	or	extreme	problems.
The	VAS	is	a	vertical	line	numbered	0-100	with	end-points	la-
beled	as	 “the	best	health	 you	 can	 imagine”	 (100)	 and	 “the	worst	
health	you	can	imagine”	(0).	The	person	is	asked	to	mark	an	X	on	
the scale to indicate how his/her health is on the day of assess-
ment.	Calculated	index	values	are	compared	to	an	average	German	
population,	 with	 index	 values	 ranging	 from	 0.205	 to	 1.00	 (1.00	
indicating	full	health).	The	reliability	and	validity	of	the	EQ5D-5L	
questionnaire were reported in previous studies.39-42	 It	 also	 has	
been	assessed	via	the	examination	of	patients	with	several	differ-
ent	diseases	in	numerous	countries	and	is	used	in	the	INTERMACS	
report,	 which	 describes	 the	 QoL	 of	 patients	 treated	 with	 assist	
devices.43-47
2.4 | Statistical analysis
Statistical	analysis	of	the	data	was	performed	with	IBM	SPSS	Statistic	
software	 (version	 24.	 IBM	Corporation)	 and	Microsoft	 Excel	 (ver-
sion	12.1.0	for	Mac).	Analysis	of	the	Kidscreen	data	was	performed	
according	 to	 the	 instruction	 on	 the	 Kidscreen	Manual.48	 The	 EQ-
5D-5L	 index	values	were	calculated	with	the	EQ-5D-5L	Crosswalk	
Index	Value	Calculator,	which	can	be	downloaded	from	the	EuroQoL	
website	 (https	://euroq	ol.org/eq-5d-instr	ument	s/eq-5d-5l-about/	
valua	tion-stand	ard-value-sets/cross	walk-index-value-calcu	lator/	).49 
Descriptive analysis was carried out for the entire cohort with con-
tinuous	variables	reported	as	percentage,	mean,	median,	range,	and	
standard deviation. P-values were calculated using the nonparamet-
ric	Wilcoxon	signed-rank	test.
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3  | RESULTS
3.1 | Patients’ characteristic and clinical data
Out	of	a	total	of	145	pediatric	heart	transplant	patients,	39	patients	
(20	males/19	 females),	 ages	 ranging	 from	 7.34	 to	 24.31	 years	 old	
(mean	8.86,	median	8.51),	were	implanted	with	a	VAD	at	the	depart-
ment	of	pediatric	cardiology	of	the	Großhadern	campus	of	the	LMU	
hospital	in	Munich	between	1992	and	2016	(Figure	1).	Out	of	these	
39	patients,	28	received	the	assist	device	as	a	bridge	to	transplan-
tation,	1	patient	as	a	BTR,	while	10	patients	died	during	 the	VAD	
therapy.
Most	patients	were	bridged	using	a	pulsatile	flow	device	(Berlin	
Heart	Excor®:	n	=	23,	Medos	VAD:	n	=	8,	and	Novacor-LVAD:	n	=	2).	
Continuous	flow	devices	were	used	in	5	patients	(HeartWare	VAD:	
n	=	4	and	 Jarvik	2000:	n	=	1).	One	patient	became	an	ECMO	 im-
planted	as	a	bridge	to	transplantation,	without	using	a	further	assist	
device.
On	 average,	 patients	 spent	 74.26	 days	 with	 a	 VAD	 (median	
29	days	[1-484	days]).	Eleven	patients	required	ECMO	therapy	be-
fore or after their VAD therapy.
Seven	patients	died	 following	Htx.	The	 leading	cause	of	death	
is specified in Table 1. The 1-year post-transplantation survival 
percentage	 of	 the	 sample	was	 92.86%,	 85.71%	 after	 5	 years,	 and	
78.57%	after	10	years.	Demographics	of	 the	22	 included	patients	
are	shown	in	Table	2	and	Figure	1.
3.2 | Neurological examination using the 
assessment for MND
The	MND	 assessment	 is	 considered	 to	 be	 an	 excellent	 tool	 for	
detecting and classifying neurological dysfunction in seemingly 
healthy patients.50	 Some	 of	 the	 patients	 had	 known	 neurologi-
cal	diseases.	For	this	reason,	two	patients	with	a	known	unilateral	
motoric deficit were classified using more common motor tests. 
Specifically,	the	GMFCS	(http://www.klini	kum.uni-muenc	hen.de/
mashu	p/blaet	terka	talog_ispz_gmfcs/	blaet	terka	talog/	pdf/compl	
ete.pdf)	 and	Manual	 Ability	 classification	 system-MACS	 (http://
www.macs.nu)	 were	 employed.	 Both	 patients	 were	 classified	
as	GMFCS	1	and	MACS	2.	Etiology	of	 the	unilateral	motor	defi-
cits is a presumed complication of the period of time after VAD 
F I G U R E  1   Description of inclusion process
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implantation.	Two	patients	could	not	be	examined	due	 to	a	psy-
chomotor	 deficit	 and	 difficulties	 of	 comprehension.	 It	 was	 too	
difficult	 to	 perform	 the	 standardized	 neurological	 examination	
in	one	patient	because	of	excessive	shyness	and	in	four	toddlers	
(aged	1-3	years)	during	routine	appointments;	however,	besides	a	
speech	delay	 in	one	patient,	 there	were	no	neurological	 deficits	
documented in their medical records.
The	MND	assessment	was	performed	on	a	total	of	13	patients,	
≥6	years,	without	apparent	neurological	deficit,	 in	order	 to	detect	
even	slight	neurological	impairment.	Eleven	patients	had	normal	ex-
amination	 results,	 1	 patient	 showed	 a	 simple	MND,	 and	1	 patient	
presented	with	a	complex	MND.
3.3 | Epitrack®
The	 Epitrack®	 test	was	 completed	 by	 15	 patients.	 Three	 patients	
could	 not	 complete	 the	 questionnaire	 due	 to	 task	 comprehension	
difficulties	(n	=	2)	and	excessive	shyness	(n	=	1).	Four	patients	were	
under 6 years old at the time of the test.
The	average	 result	of	 the	Epitrack®	 Junior	 test,	 completed	by	7	
patients,	 was	 30.57	 (min	 27,	 max	 36),	 while	 the	 average	 Epitrack® 
Adult	test	result	was	30.25	(min	10,	max	39),	completed	by	8	patients.	
A	majority	of	patients	scored	an	“average”	result	(n	=	6),	followed	in	
frequency	by	the	results	“Impaired”	 (n	=	4),	“borderline”	 (n	=	3),	and	
“good”	(n	=	2).	The	results	of	the	Epitrack® test are presented in Table 3.
3.4 | Quality of life
3.4.1 | Kidscreen-52
A	 total	 of	 7	 children	 and	11	parents	 completed	 the	 self-	 and	 proxy	
version	of	 the	Kidscreen-52	Questionnaire.	Children	estimated	 their	
HRQoL	 similar	 to	 the	 age-matched	 German	 reference	 population,	
without	significant	difference	(Table	4).	In	the	proxy	version	(parents	
estimating	QoL	of	their	children),	the	score	in	the	autonomy	scale	was	
significantly lower compared to the German reference sample. The 
difference in the responses to the financial resources scale between 
self-	and	proxy	versions	of	the	questionnaire	did	not	reach	significance.	
Parents rated all other scales similar to the German reference popula-
tion,	meaning	that	they	do	not	perceive	their	child	to	suffer	from	any	
disadvantages	in	daily	life,	compared	to	healthy	children	(see	Table	5).	
The	comparison	of	 the	HRQoL	 scores	given	by	patients	 themselves	
(n	=	7)	to	scores	given	by	parents	(n	=	7)	is	presented	in	Figure	2	and	
Table 6. Parents estimated social acceptance and bullying to be a sig-
nificantly	larger	burden	than	their	children,	while	children	scored	their	
financial resources significantly higher.
 n = 15 Mean Median Min Max SD
Total score
Epitrack®	Jr	
n	=	7
 30.57 31 27 36 2.99
Epitrack® adult 
n	=	8
 30.25 31.5 10 39 9.099
Classification in
Good 2	(9.1%)      
Epitrack® 
Junior
1      
Epitrack® 
adult
1      
Average 6	(27.3%)      
Epitrack® 
Junior
3      
Epitrack® 
adult
3      
Borderline 3	(13.6%)      
Epitrack® 
Junior
1      
Epitrack® 
adult
2      
Impaired 4	(18.2%)      
Epitrack® 
Junior
2      
Epitrack® 
adult
2      
TA B L E  3  Epitrack®	results	of	n	=	15	
patients
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3.4.2 | EQ-5D-5L
Eight	 adult	 patients	 (≥18	 years)	 completed	 the	 EQ-5D-5L	 ques-
tionnaire.	 Answers	 to	 the	 descriptive	 part	 of	 the	 EQ-5D-5L	
questionnaire	 are	 provided	 in	 Table	 7.	 Calculated	 index	 values	
in comparison with a German reference population are shown in 
Table	 8.	 Both	 the	 index	 values	 and	 the	 results	 of	 the	VAS	were	
similar	 to	 the	German	reference	population,	 indicative	 reflecting	
a	high	QoL.
4  | DISCUSSION
After	over	50	years	of	pediatric	Htx,	this	therapy	option	has	become	
well established.51 The VAD treatment has also grown in importance 
over	the	years,	in	both	the	pediatric	and	adult	fields,	and	now	repre-
sents an often used bridge-to-transplant or bridge-to-recovery op-
tion.52	 It	 is	 therefore	 critical	 to	 assess	 possible	 complications	 and	
long-term outcome of these therapies.
Possible	side	effects	of	Htx	and	of	assist	device	therapy	are	neuro-
logical events.52	The	implantation	of	an	assist	device	or	a	Htx	requires	
the	use	of	a	cardiopulmonary	bypass,	with	known	potential	risks	for	
embolic	stroke.15,18	Further,	during	assist	device	therapy,	a	strict	an-
ticoagulation protocol must be carried out. This leads to an increased 
risk	for	anticoagulation	drug-associated	complications.	These	can	man-
ifest	as	acute	bleeding,	stroke,	and	further	neurological	dysfunction.	
Besides	acute	events,	 it	 is	also	conceivable	that	these	therapies	may	
affect	long-term	motor	and	executive	functioning.
HRQoL	 is	 an	 important	 outcome	 indicator	 for	 children	 with	
neurological	disabilities	and	might	be	influenced,	among	others,	by	
motor	functioning	and	psychosocial	domains	like	cognition,	behav-
ior,	and	education.53,54
In	 children	 with	 VAD	 and	 Htx,	 outcome	 studies	 often	 focus	
on	technical	details,	 survival,	and	medication.55-58	Therefore,	we	
aimed	 to	 examine	 motor	 outcomes,	 executive	 functioning,	 and	
HRQoL,	as	 these	outcome	parameters	are	 linked	one	 to	another	
and	might	 reflect	 the	 participation	 of	VAD	 and	Htx	 survivors	 in	
daily life.
We	examined	22	patients	 that	 received	an	assist	device	and	a	
heart transplant at the department of pediatric cardiology at the 
university	 hospital	 of	 the	 Ludwig-Maximilians-University	 Munich,	
campus	Großhadern,	between	1992	and	2016.
With	respect	to	motor	neurological	deficits,	4	patients	were	al-
ready	diagnosed	with	unilateral	motor	deficits	(presumed	complica-
tion	during	time	with	VAD:	n	=	2)	and	psychomotor	deficit	(unknown	
etiology:	n	=	2).
The	majority	of	 the	other	patients	 (≥6	years)	who	participated	
showed	normal	neurological	examination	results	using	the	MND	as-
sessment	protocol	(n	=	11	out	of	13).
In	the	cohort,	one	patient	had	a	simple	MND	and	one	patient	
presented	 with	 a	 complex	 MND.	 A	 simple	 MND	 is	 a	 common	
finding in children and may be grouped with normal neurological 
findings.	Simple	MND	s	can	be	considered	a	slight	neurological	dif-
ference and may only have limited clinical significance.29,59 Peters 
et al showed that in a general population many children were 
found	to	have	simple	or	complex	MNDs	(27%	vs	22%).	Broström	et	
al	examined	prematurely	born	patients	using	the	MND	assessment	
tool.	 It	was	 found	 that	64%	presented	with	 a	normal	neurology,	
28.7%	with	 a	 simple	MND	 and	 7.5%	with	 a	 complex	MND.50	 In	
another	 study,	 Kavas	 et	 al	 assessed	 children	with	 a	 birthweight	
<1500	 g.	 The	 analysis	 of	 this	 prospective	 longitudinal	 study	
showed	that,	among	several	potential	factors,	a	low	Apgar	score,	
history	of	sepsis,	and	a	long	duration	of	hospitals	stay	correlated	
with	an	increased	risk	for	a	simple	MND.60	However,	these	results	
are not directly comparable to ours due to the investigation of dif-
ferent	diseases	and	risk	factors.	Nonetheless,	compared	to	results	
of	these	and	further	studies,	our	findings	show	good	results	in	the	
MND	examination	of	this	cohort.	They	are	comparable	to	those	of	
a healthy population.50,59-61
On	the	one	hand,	studies	of	the	motor	and	executive	functioning	
of patients treated with a VAD suggest a benefit of this therapy due 
to better cerebral perfusion.21,62,63	On	the	other	hand,	VAD	therapy	
TA B L E  4  Differences	between	patients	(n	=	7)	and	German	
reference	sample	assessed	by	the	nonparametric	Wilcoxon	signed-
rank	test
Kidscreen dimensions P-value
Physical well-being .9063
Psychological well-being .8125
Moods and emotions .5469
Self-perception .9219
Autonomy .7969
Parent relation and home life .3750
Financial	resources .6719
Social	support	and	peers .5313
School	environment .3594
Social	acceptance	and	bullying .1875
TA B L E  5   Differences between child´s quality of life scored by 
the	parents	(n	=	11)	and	German	reference	sample	assessed	by	the	
nonparametric	Wilcoxon	signed-rank	test
Kidscreen dimensions P-value
Physical well-being .6201
Psychological well-being .3086
Moods and emotions .4014
Self-perception .4375
Autonomy .0225*
Parent relation and home life .2246
Financial	resources .0576
Social	support	and	peers .5146
School	environment .3730
Social	acceptance	and	bullying .2285
*P	<	.05	are	considered	to	be	significant.	
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and	Htx	are	still	associated	with	a	high	risk	of	brain	injury	and	thus	
neurological complications. VanderPluym et al previously described 
neuroimaging	 results,	 obtained	 during	 and	 after	 VAD	 therapy,	
screening	 for	 brain	 injuries	 in	 children	 under	 6	 years	 old,	 bridged	
with	the	Berlin	Heart	excor®.	75%	of	patients	were	reported	to	show	
brain	 injury	 during	 neuroimaging	 at	 some	point	 in	 their	 life,	while	
31%	were	found	to	have	brain	 injuries	during	VAD	therapy.	 In	this	
study,	 abnormal	neuroimaging	generally	 correlated	with	an	abnor-
mal	neurological	and	physical	examination.	It	was	also	found	that	ab-
normal	physical	examination	often	correlated	with	lower	IQ	scores.	
Only	2	patients	(out	of	10)	had	abnormal	neuroimaging	results	with	a	
neurological	and	physical	examination	within	normal	limits.64
Neurological	impairment	may	be	of	a	motoric	nature,	but	can	also	
affect	executive	functioning.	With	this	in	mind,	the	cognitive	state	
of	our	patients	was	examined.	Though	the	Epitrack® was originally 
designed	to	monitor	attention	and	executive	functioning	in	patients	
with	epilepsy,	it	is	a	promising	screening	test	in	patients	with	other	
neurological	disorders,	also.26	 In	clinical	practice,	detected	deficits	
should be further investigated through a comprehensive neuropsy-
chological	examination,	while	considering	the	context	of	the	child´s	
educational and social performance.
In	 this	 cohort,	Epitrack® testing revealed slight impairments in 
some	cases;	however,	 results	generally	 indicated	quite	positive	re-
sults	 considering	 the	 high	 risk	 for	 neurological	 events	 during	 this	
therapy.	On	average,	children	performed	7.36%	and	adults	13.82%	
lower than the reference population.22,27
Other	 studies	about	 the	cognitive	outcome	after	VAD	therapy	
are	 very	 promising.	 Chinnock	 et	 al	 described	 the	 developmental	
outcome	of	 children	after	Htx	as	within	a	 low	 to	average	 range.65 
Jahnukainen	 et	 al	 found	 that	 the	 cognitive	 outcome	 of	 children	
bridged with an assist device was not worse than that of children 
who	did	not	need	an	assist	device	before	their	Htx.9
As neurological impairment and cognition problems can greatly 
affect	patients´	lives,	a	main	objective	of	this	study	was	to	examine	
patients’	subjective	assessment	about	their	QoL.
There	are	few	studies	evaluating	HRQoL	after	Htx	in	childhood	
or	adolescence	 (with	or	without	VAD	as	a	bridge	to	 transplanta-
tion).66-69	 In	 this	 study,	 patients	 reported	 an	 average	 daily	 QoL	
F I G U R E  2  Quality	of	life	(mean)	scored	
by	patients	(n	=	7),	their	parents	(n	=	7),	
and the German reference population
TA B L E  6   Differences between child's quality of life scored 
by	patients	(n	=	7)	and	their	parents	(n	=	7)	assessed	by	the	
nonparametric	Wilcoxon	signed-rank	test
Kidscreen dimensions P-value
Physical well-being .5781
Psychological well-being .2969
Moods and emotions .5781
Self-perception 1.0000
Autonomy .3750
Parent relation and home life .6563
Financial	resources .0313*
Social	support	and	peers .1563
School	environment .5469
Social	acceptance	and	bullying .0156*
*P	<	.05	are	considered	to	be	significant.	
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of	79.38	(68.32-90.42)	 in	the	VAS	of	the	EQ5D-5L.	Compared	to	
the	 results	 of	 the	 INTERMACS	 report,	 where	 patients	 reported	
an	average	daily	QoL	of	35.3	before	VAD	 implantation	and	70.3	
12	months	after	implantation,	the	QoL	seems	to	be	higher	among	
this cohort.52
In	summary,	results	are	discrepant:	While	some	studies	found	
a	 similar	 QoL	 in	 heart	 transplant	 recipients,	 compared	 to	 a	 ref-
erence	 sample	 of	 healthy	 persons,	 others	 detected	 significantly	
lower psychosocial and physical functioning scores.52,70 Wille et 
al	asked	756	German	children	about	their	QoL	using	a	VAS	which	
was	scored	with	an	average	of	83.7.71	 In	 this	cohort,	all	patients	
scored	 their	HRQoL	comparable	 to	 the	German	reference	popu-
lation,	which	underlines	 that	 they	do	not	 suffer	 from	 significant	
limitations	in	their	daily	life.	Interestingly,	parents	estimated	social	
acceptance and bullying as a significant problem in their children´s 
lives,	compared	to	the	children	themselves.	Parents	also	estimated	
“autonomy” of their children as being significantly reduced com-
pared	 to	healthy	 children—again,	 in	 contrast	 to	normal	 scores	 in	
the children's own questionnaires. The fact that parents estimate 
QoL	as	lower	in	some	categories	than	patients	themselves	has	also	
been	described	for	other	chronic	diseases,	such	as	migraine,	and	
may reflect parents´ own fears and concerns.72
Generally,	far	lower	results	were	expected,	given	the	fact	that	
both	procedures	(Htx	and	VAD	implantation/therapy)	are	signifi-
cant	risk	factors	for	neurological	events.65,73	Other	factors,	such	
as	the	chronic	hypoxemia	due	to	heart	failure,	the	anesthetic	drugs	
used	during	surgery,	and	long	hospital	stays,	were	also	considered	
as having a potentially negative impact on children's cognitive de-
velopment.11,17	Nonetheless,	these	findings	match	the	findings	of	
previous studies.63,65	Altogether,	the	overall	motor	and	executive	
development,	 as	 well	 as	 QoL	 in	 the	 22	 included	 patients,	 were	
high.
A limiting factor of this study is the small sample size. This may 
be due to the fact that while VAD therapy has increased in impor-
tance	over	the	past	years,	it	still	remains,	similar	to	Htx,	a	relatively	
rare procedure. The only possibility for achieving a bigger sample 
size	would	be	to	conduct	large,	multicenter	studies.	It	should	also	be	
considered that 10 out of 39 patients died during VAD therapy and 
7	patients	died	in	the	following	years	after	Htx	(10-year	post-trans-
plant	survival	rate:	78.57%).	Although	survival	data	from	other	stud-
ies	in	similar	populations	showed	the	same	result,	this	still	remains	
a therapy with a high mortality rate and therefore obtaining larger 
samples may continue to be difficult.19,74-79
Due	 to	 the	 long	 observation	 period,	 the	 continuous	 technical	
medical	development,	and	the	heterogeneous	patient	group,	differ-
ent	assist	devices	were	used.	A	specific	assessment,	considering	the	
properties	of	the	different	VADs,	could	be	interesting.	It	must	also	
TA B L E  7  Answers	in	the	descriptive	part	of	the	EQ-5D-5L	
questionnaire	(8	patients,	≥18	y	old)
EQ-5D dimension Level N = 8 (%)
Mobility No	problems 8	(100.0)
Slight	problems  
Moderate problems —
Severe	problems —
Unable	to —
Missing value —
Self-care No	problems 8	(100.0)
Slight	problems —
Moderate problems —
Severe	problems —
Unable	to —
Missing value —
Usual	activity No	problems 5	(62.5)
Slight	problems 1	(12.5)
Moderate problems 2	(25.0)
Severe	problems —
Unable	to —
Missing value —
Pain/discomfort No	pain 5	(62.5)
Slight	pain 2	(25.0)
Moderate pain 1	(12.5)
Severe	pain —
Unable	to —
Missing value —
Anxiety/depression Not	anxious 5	(62.5)
Slightly	anxious 2	(25.0)
Moderately	anxious 1	(12.5)
Severely	anxious —
Extremely	anxious —
Missing value —
TA B L E  8  Calculated	EQ-5D-5L	Index	values	and	EQ-5D-5L	VAS	of	8	adult	patients	(5	patients	<25	y)	compared	to	the	German	index	
value set
 
Adult study 
population (n = 8)
Reference population (Germany)
Age 18-24 (n = 264) Age 25-34 (n = 551) Total (n = 3552)
Mean 95% CI Mean SE 95% CIa Mean SE 95% CIa Mean SE 95% CIa
EQ-5D-5L	
Index	Value
0.96 0.92-1.00 0.972 0.008 0.96-0.99 0.973 0.003 0.97-0.98 0.938 0.002 0.93-0.94
EQ-5D-5L	VAS 79.38 68.32-90.42 85.3 1.1 83.14-87.46 84.0 0.8 82.43-85.57 77.3 0.4 76.52-78.08
aEstimated	CI	of	reference	population	with	CI=(mean	±	1.96	×	standard	error	[SE])	
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be	considered	that	the	age	range	of	our	patients	is	very	variable.	It	
could therefore be interesting to analyze results of future studies in 
the	context	of	patient	age.
In	 most	 studies	 on	 assist	 device	 therapy	 and	 Htx,	 the	 main	
focal	points	are	survival	and	general	health	outcomes.	Especially,	
the	 executive	 and	motor	 outcomes	 are	 decisive	 for	 the	 integra-
tion	of	a	 child	 into	 its’	 educational,	 later	professional,	 and	 social	
environment.	Therefore,	the	Epitrack®	testing	in	particular,	which	
is	 easy	 and	 quick	 to	 perform,	 should	 be	 an	 inherent	 part	 of	 the	
post-	Htx	follow-up,	in	order	to	detect	executive	deficits	as	soon	
as	possible.	Further	studies	for	exploring	potential	follow-up	pro-
grams are warranted.
5  | CONCLUSION
The	main	objective	of	 this	 study	was	 to	 examine	 the	motoric	 and	
executive	functioning	outcomes,	as	well	as	the	HRQoL	of	patients	
who received an assist device as a bridge to transplantation or BTR 
at the department of pediatric cardiology between 1992 and 2016 
at	the	university	hospital	in	Munich.	To	assess	this,	we	used	a	battery	
of	tests	composed	of	the	MND	neurological	examination,	Epitrack® 
test,	and	Kidscreen	52/EQ-5D-5L	QoL	questionnaires.
Our	 results	 suggest,	 that	 in	 children	 with	 VAD	 for	 bridge	 to	
transplantation	 or	 BTR,	 overall	 executive	 and	motor	 development	
is	encouragingly	strong,	which	may	be	reflected	in	a	high	QoL.	Most	
patients	 seem	 to	 achieve	 normally	 functioning	 social,	 academic,	
and	professional	lives.	Further	studies	to	confirm	these	findings	are	
warranted.
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